James Heyes, PhD
April 8, 2025
James Heyes has served as Chief Executive Officer of Genevant Sciences Corporation since March 2025. Previously, he was Genevant’s Chief Scientific Officer and, prior to that, Genevant’s Senior Vice President, Technology Development. Before joining Genevant, James was Vice President, Drug Delivery of Arbutus Biopharma. He brings over 20 years of experience in lipid chemistry and nucleic acid drug delivery and is an inventor of next generation lipid nanoparticle and ligand conjugate technology, with more than 20 issued and published U.S. patents in the area. James designed the lipid components enabling the first demonstration of RNA interference in primates and the advancement of 13 clinical candidates. He holds a PhD in Medicinal and Pharmaceutical Chemistry from the University of London and a BSc in Chemistry from the University of Manchester.